1. Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESHESC Guidelines for the management of arterial hypertension. European Heart Journal. 2013; doi:10.1093/eurheart/eht151.
2. Streicher JM, Wang Y. The role of COX-2 in heart pathology. Cardiovasc Hematol Agents Med Chem. 2008; 6 (1): 69–79.
3. Głuszek J, Tykarski A, Jankowska K. Is it recommended simultaneous use of acetylsalicylic acid and angiotensin converting enzyme inhibitors? Pol Arch Med Wewn. 2005; 114 (3): 906–12.
4. Borghi C, Ambrosioni E, Novo S, et al. Comparison between zofenopril and ramipril in combination with acetylsalicylic acid in patients with left ventricular systolic dysfunction after acute myocardial infarction: results of a randomized, double-blind, parallel-group, multicenter, European study (SMILE-4). Clin Cardiol. 2012;35 (7): 416–23.
5. Borghi C, Ambrosioni E, Omboni S, et al. Cost-effectiveness of zofenopril in patients with left ventricular systolic dysfunction after acute myocardial infarction: a post hoc analysis of SMILE-4. Clinicoecon Outcomes Res. 2013 Jul 8; 5: 317–25.
6. Borghi C, Cosentino ER, Rinaldi ER, Cicero AF. Effect of zofenopril and ramipril on cardiovascular mortality in patients with chronic heart failure. Am J Cardiol. 2013;112 (1):90–3.
7. Borghi C, Bacchelli S, Degli Esposti D. Long-term clinical experience with zofenopril. Expert Rev Cardiovasc Ther. 2012; 10 (8): 973–82.
8. Bozcali E, Dedeoglu DB, Karpuz V, et al. Cardioprotective effects of zofenopril, enalapril and valsartan against ischaemia/reperfusion injury as well as doxorubicin cardiotoxicity. Acta Cardiol. 2012; 67 (1): 87–96.
9. Omboni S, Borghi C. Zofenopril and incidence of cough: a review of published and unpublished data. Ther Clin Risk Manag. 2011;7:459–71.
10. Cacciatore F, Bruzzese G, Vitale DF, et al. Effects of ACE inhibition on circulating endothelial progenitor cells, vascular damage, and oxidative stress in hypertensive patients. Eur J Clin Pharmacol. 2011; 67 (9):877–83.
11. Uzar E, Acar A, Evliyaoğlu O, et al. The antioxidant and anti-apoptotic effects of nebivolol and zofenopril in a model of cerebral ischemia/ reperfusion in rats. Prog Neuropsychopharmacol Biol Psychiatry. 2012; 36 (1):22–8.
12. Borghi C, Cicero AF, Bacchelli S, et al. Survival of Myocardial Infarction Long-term Evaluation (SMILE) Study. Serum cholesterol levels on admission and survival in patients with acute myocardial infarction treated with zofenopril: a post hoc analysis of the Survival of Myocardial Infarction Long-term Evaluation trial. Fundam Clin Pharmacol. 2009; 23 (5):641–8.
13. Bălan H, Popescu E, Angelescu G. Comparing different treatment schedules of Zomen (zofenopril). Rom J Intern Med. 2011;49 (1):75–84.
14. Carnicelli V, Frascarelli S, Zucchi R. Effect of acute and chronic zofenopril administration on cardiac gene expression. Mol Cell Biochem. 2011; 352 (1–2):301–7.
15. Napoli C, Bruzzese G, Ignaro L, et al. Long-term treatment with sulfhydryl angiotensin-converting enzyme inhibition reduces carotid intima-media thickening and improves the nitric oxideoxidative stress pathways in newly diagnosed patients with mild to moderate primary hypertension. Cardiovascular Therapy and Prevention. 2012; 11: 93–101. Russian (Наполи К, Бруцессе Дж, Игнарро Л. Дж. и др. Долгосрочная терапия сульфгидрильным ингибитором ангиотензин-превращающего фермента замедляет утолщение комплекса интима-медиа сонных артерий, улучшает показатели обмена оксида азота и окислительного стресса у пациентов с впервые диагностированной первичной мягкой артериальной гипертонией. Кардиоваскулярная терапия и профилактика. 2012; 11:93– 101).
16. Morozova TE, Andrushchitsina TB. Possible antihypertensive interventions in comorbid coronary heart disease and systemic hypertension. Russ J Cardiol. 2013; 4:88–94. Russian (Морозова Т.Е., Андрущицина Т.Б. Возможности комбинированной антигипертензивной терапии при сочетании артериальной гипертензии и ишемической болезни сердца. Российский кардиологический журнал. 2013; 4:88–94).
